Boston's Promus Element CE marked for larger group of patients
This article was originally published in Clinica
Boston Scientific has CE marked its Promus Element everolimus-eluting stent for use in patients with diabetes mellitus and those experiencing an acute myocardial infarction (AMI). The Natick, Massachusetts firm says that the new indications are "important additions, especially as the prevalence of diabetes continues to increase dramatically worldwide". Promus Element was originally CE marked for sale in Europe in late 2009 (www.clinica.co.uk, 3 November 2009). Approval in both the US and Japan is expected in mid-2012.